Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of C?C motif chemokine receptor 6

被引:23
作者
Jin, Liyuan [1 ,2 ]
Cao, Lei [3 ]
Zhu, Yingjie [1 ,2 ]
Cao, Jiani [1 ]
Li, Xiaoyan [1 ]
Zhou, Jianxia [1 ,2 ]
Liu, Bing [4 ]
Zhao, Tongbiao [1 ,2 ]
机构
[1] Chinese Acad Sci, Inst Stem Cell & Regenerat, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China
[2] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
[3] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Thorac Surg, Beijing 100730, Peoples R China
[4] Acad Mil Med Sci, Affiliated Hosp, Translat Med Ctr Stem Cells, State Key Lab Prote,Ivy Translat Med Ctr 307,Lab, Beijing 100071, Peoples R China
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
CCR6; CCL20; CAR-T; Migration; Lung cancer; ANTITUMOR-ACTIVITY; CANCER; IMMUNOTHERAPY; ANTIBODY; THERAPY; IL-7; INFILTRATION; STRATEGIES; MANAGEMENT; PROSPECTS;
D O I
10.1016/j.scib.2020.12.027
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Chimeric antigen receptor-T (CAR-T) cells have limited therapeutic efficacy against solid tumors, partially due to their limited ability to reach and invade into the neoplastic foci. By gene expression profiling interactive analysis, we identified that the C?C motif chemokine ligand (CCL) 20 is highly expressed in lung and other most incidence and/or mortality cancers such as colon, rectum, stomach, and liver cancers. Forced expression of C?C motif chemokine receptor 6 (CCR6), the biunique receptor of CCL20, results in robust trafficking of CAR-T cells toward CCL20-secreting tumor cells. In a lung cancer xenograft mouse model, CCR6-expressing CAR-T cells efficiently migrate to and infiltrate into solid tumors upon infusion, leading to effective tumor clearance and significantly prolonged survival of tumor-bearing mice. In addition, culturing CCR6-CAR-T cells with interleukin (IL)-7 and IL-15 further improved their anti-lung cancer activity. Our findings provide supporting evidence for the clinical development of chemokine receptorengineered CAR-T cells for solid tumor immunotherapy. ? 2020 Science China Press. Published by Elsevier B.V. and Science China Press. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:803 / 812
页数:10
相关论文
共 50 条
  • [11] Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies
    Greco, Beatrice
    Malacarne, Valeria
    De Girardi, Federica
    Scotti, Giulia Maria
    Manfredi, Francesco
    Angelino, Elia
    Sirini, Camilla
    Camisa, Barbara
    Falcone, Laura
    Moresco, Marta Angiola
    Paolella, Katia
    Di Bono, Mattia
    Norata, Rossana
    Sanvito, Francesca
    Arcangeli, Silvia
    Doglioni, Claudio
    Ciceri, Fabio
    Bonini, Chiara
    Graziani, Andrea
    Bondanza, Attilio
    Casucci, Monica
    SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (628)
  • [12] Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors
    Du, Xin
    Darcy, Phillip K.
    Wiede, Florian
    Tiganis, Tony
    MOLECULAR AND CELLULAR BIOLOGY, 2022, 42 (03)
  • [13] Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy
    Katiyar, Vatsala
    Chesney, Jason
    Kloecker, Goetz
    CANCERS, 2023, 15 (14)
  • [14] DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells
    Zhao, Ruocong
    Cheng, Lin
    Jiang, Zhiwu
    Wei, Xinru
    Li, Baiheng
    Wu, Qiting
    Wang, Suna
    Lin, Simiao
    Long, Youguo
    Zhang, Xuchao
    Wu, Yilong
    Du, Xin
    Pei, Duanqing
    Liu, Pentao
    Li, Yangqiu
    Cui, Shuzhong
    Yao, Yao
    Li, Peng
    ONCOIMMUNOLOGY, 2019, 8 (01):
  • [15] Efficacy and safety of chimeric antigen receptor-T cells in the treatment of B cell lymphoma: a systematic review and meta-analysis
    Zheng, Xiao-Hong
    Zhang, Xi-You
    Dong, Qian-Qian
    Chen, Feng
    Yang, Shou-Bo
    Li, Wen-Bin
    CHINESE MEDICAL JOURNAL, 2020, 133 (01) : 74 - 85
  • [16] Chimeric antigen receptor-T cells targeting AFP-GPC3 mediate increased antitumor efficacy in hepatocellular carcinoma
    Li, Mingxing
    Chen, Tailin
    Huang, Rongshi
    Cen, Yanhui
    Zhao, Feilan
    Fan, Rong
    He, Guozhen
    ARAB JOURNAL OF GASTROENTEROLOGY, 2025, 26 (01) : 84 - 93
  • [17] Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice
    Chen, Muhua
    Sun, Ruixin
    Shi, Bizhi
    Wang, Yi
    Di, Shengmeng
    Luo, Hong
    Sun, Yansha
    Li, Zonghai
    Zhou, Min
    Jiang, Hua
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 113
  • [18] Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates
    Kim, Ye-Jin
    Li, Wei
    Zhelev, Doncho V. V.
    Mellors, John W. W.
    Dimitrov, Dimiter S. S.
    Baek, Du-San
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [19] c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo
    Huang, Xiaochen
    Guo, Jiaojiao
    Li, Tao
    Jia, Lizhou
    Tang, Xiaojun
    Zhu, Jin
    Tang, Qi
    Feng, Zhenqing
    JOURNAL OF BIOMEDICAL RESEARCH, 2022, 36 (01): : 10 - 21
  • [20] Construction of chimeric antigen receptor-modified T cells targeting EpCAM and assessment of their anti-tumor effect on cancer cells
    Zhou, Yan
    Wen, Ping
    Li, Mingmei
    Li, Yaqi
    Li, Xiao-An
    MOLECULAR MEDICINE REPORTS, 2019, 20 (03) : 2355 - 2364